EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Enlicitide: The first oral PCSK9 inhibitor approved for treatment of hypercholesterolemia

Yueyi Sun, Jianjun Gao

Drug Discoveries & Therapeutics · 2026

DOI: 10.5582/ddt.2026.01051 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Discoveries & Therapeutics, 2026. Verfasst von Yueyi Sun und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, Shandong, China. Hauptthemen laut MEDLINE: PCSK9 Inhibitors, Hypercholesterolemia, Anticholesteremic Agents. Die Arbeit nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypercholesterolemia, and particularly elevated low-density lipoprotein cholesterol (LDL-C), is a major causal factor in atherosclerotic cardiovascular disease (ASCVD) and contributes substantially to coronary heart disease, ischemic stroke, and peripheral artery disease. Statins remain the cornerstone of lipid-lowering therapy, while ezetimibe and injectable proprotein convertase subtilisin/kexin 9 (PCSK9) targeted agents are added when further LDL-C reduction is required. However, concerns about injections, cost, accessibility, and treatment inertia have limited the use of existing PCSK9 therapies, creating a need for potent oral alternatives. Enlicitide, approved by the US Food and Drug Administration in July 2026, is the first approved oral PCSK9 inhibitor. This macrocyclic peptide blocks the interaction between circulating PCSK9 and hepatic LDL receptors, thereby increasing receptor recycling and LDL-C clearance. In the phase III CORALreef Lipids and CORALreef HeFH trials, once-daily enlicitide reduced LDL-C by approximately 60%, and the effect was maintained for up to 52 weeks. Adverse event rates were generally similar to those observed with a placebo. Nevertheless, those trials primarily evaluated LDL-C reduction rather than cardiovascular outcomes, and their duration was insufficient to establish long-term safety. The ongoing CORALreef Outcomes trial will determine whether enlicitide-mediated LDL-C reduction translates into fewer major cardiovascular events and will help define its long-term clinical role.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PCSK9 InhibitorsHypercholesterolemiaAnticholesteremic AgentsHumansProprotein Convertase 9Cholesterol, LDLAdministration, OralDrug ApprovalAnimals

Stichwörter der Autor:innen

ASCVDLDL-CLDLRPCSK9enlicitide

Substanzen

PCSK9 InhibitorsPCSK9 protein, humanProprotein Convertase 9Anticholesteremic AgentsCholesterol, LDL

Autor:innen und Institutionen

  • Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, Shandong, China.

Zitieren

APA

Sun, Y., & Gao, J. (2026). Enlicitide: The first oral PCSK9 inhibitor approved for treatment of hypercholesterolemia. Drug Discoveries & Therapeutics. https://doi.org/10.5582/ddt.2026.01051

Vancouver

Sun Y, Gao J. Enlicitide: The first oral PCSK9 inhibitor approved for treatment of hypercholesterolemia. Drug Discoveries & Therapeutics. 2026. doi:10.5582/ddt.2026.01051

BibTeX
@article{Sun2026,
  author = {Sun, Yueyi and Gao, Jianjun},
  title = {Enlicitide: The first oral PCSK9 inhibitor approved for treatment of hypercholesterolemia},
  journal = {Drug Discoveries & Therapeutics},
  year = {2026},
  doi = {10.5582/ddt.2026.01051}
}
Kostenlos starten →